Immedica completes acquisition of Marinus Pharmaceuticals, expanding its portfolio in rare diseases.
Imfinzi lowers risk of distant metastases and death in bladder cancer compared to neoadjuvant chemotherapy alone.
Relativity-098 trial did not meet primary endpoint of recurrence-free survival in stage III-IV melanoma.